Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Change in Accured Expenses (2016 - 2025)

Regenxbio (RGNX) has 12 years of Change in Accured Expenses data on record, last reported at $3.2 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 377.0% year-over-year to $3.2 million; the TTM value through Dec 2025 reached $229000.0, up 108.78%, while the annual FY2025 figure was $229000.0, 108.78% up from the prior year.
  • Change in Accured Expenses reached $3.2 million in Q4 2025 per RGNX's latest filing, up from -$16000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $33.5 million in Q3 2022 and bottomed at -$26.5 million in Q1 2022.
  • Average Change in Accured Expenses over 5 years is $423550.0, with a median of $76000.0 recorded in 2022.
  • Peak YoY movement for Change in Accured Expenses: tumbled 176.53% in 2021, then surged 2928.57% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at $291000.0 in 2021, then plummeted by 42.27% to $168000.0 in 2022, then soared by 2928.57% to $5.1 million in 2023, then tumbled by 122.82% to -$1.2 million in 2024, then soared by 377.0% to $3.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $3.2 million in Q4 2025, -$16000.0 in Q3 2025, and -$16000.0 in Q2 2025.